Knights of Columbus Asset Advisors LLC Has $6.58 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Knights of Columbus Asset Advisors LLC reduced its holdings in Natera, Inc. (NASDAQ:NTRA) by 11.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,969 shares of the medical research company’s stock after selling 7,456 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Natera were worth $6,581,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of NTRA. Marshall Wace LLP bought a new position in Natera in the 1st quarter worth approximately $264,000. Dimensional Fund Advisors LP raised its position in Natera by 428.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 51,356 shares of the medical research company’s stock worth $5,111,000 after purchasing an additional 41,629 shares during the last quarter. Swiss National Bank raised its position in Natera by 8.0% in the 1st quarter. Swiss National Bank now owns 165,800 shares of the medical research company’s stock worth $16,835,000 after purchasing an additional 12,300 shares during the last quarter. BlackRock Inc. raised its position in Natera by 3.1% in the 1st quarter. BlackRock Inc. now owns 6,432,039 shares of the medical research company’s stock worth $653,108,000 after purchasing an additional 194,745 shares during the last quarter. Finally, Oppenheimer & Co. Inc. bought a new position in Natera in the 1st quarter worth approximately $284,000. Hedge funds and other institutional investors own 93.97% of the company’s stock.

In related news, insider Daniel Rabinowitz sold 446 shares of the company’s stock in a transaction on Thursday, September 23rd. The shares were sold at an average price of $125.67, for a total value of $56,048.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 80,826 shares of the company’s stock in a transaction on Friday, September 10th. The stock was sold at an average price of $119.72, for a total transaction of $9,676,488.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 225,573 shares of company stock valued at $26,279,880. 10.86% of the stock is owned by corporate insiders.

NTRA opened at $118.12 on Monday. The company has a quick ratio of 3.59, a current ratio of 3.74 and a debt-to-equity ratio of 0.94. Natera, Inc. has a 12 month low of $64.42 and a 12 month high of $129.09. The company has a fifty day simple moving average of $114.75 and a 200 day simple moving average of $107.66. The stock has a market cap of $11.08 billion, a P/E ratio of -32.19 and a beta of 1.26.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 5th. The medical research company reported ($1.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.27). Natera had a negative net margin of 62.31% and a negative return on equity of 74.29%. The firm had revenue of $142.03 million during the quarter, compared to the consensus estimate of $140.50 million. On average, equities research analysts expect that Natera, Inc. will post -4.63 earnings per share for the current fiscal year.

NTRA has been the subject of several research analyst reports. Zacks Investment Research cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, July 28th. Craig Hallum upped their target price on shares of Natera from $134.00 to $139.00 and gave the company a “buy” rating in a research report on Tuesday, July 20th. BTIG Research upped their target price on shares of Natera from $155.00 to $160.00 and gave the company a “buy” rating in a research report on Friday, August 6th. SVB Leerink upped their target price on shares of Natera from $140.00 to $160.00 and gave the company an “outperform” rating in a research report on Monday, June 21st. Finally, Piper Sandler upped their target price on shares of Natera from $155.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Natera presently has a consensus rating of “Buy” and a consensus price target of $138.27.

About Natera

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

Featured Article: Do equity income investments outperform growth and income investments?

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.